NBP

NovaBridge Biosciences

Phase 3 AI-extracted

givastomig

HER2-negative metastatic gastric cancer

Countdown

177days

Phase 3 readout · ~ Dec 31, 2026 estimated

What's at stake Phase 3 trial results for givastomig in HER2-negative metastatic gastric cancer are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 12h ago

“potential to begin Accelerated Approval Pathway Phase 3 study as early as Q4 2026”

Add to calendar Post on X Reddit

Provenance